Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-03
2007-04-03
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S247000, C514S183000
Reexamination Certificate
active
11118065
ABSTRACT:
The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.
REFERENCES:
patent: 4735958 (1988-04-01), Roth et al.
patent: 4808621 (1989-02-01), Roth et al.
patent: 4957971 (1990-09-01), Picard et al.
patent: 4980160 (1990-12-01), Goldberg et al.
patent: 5013749 (1991-05-01), Watson et al.
patent: 5102893 (1992-04-01), Picard et al.
patent: 5190029 (1993-03-01), Byron et al.
patent: 5376359 (1994-12-01), Johnson
patent: 5776434 (1998-07-01), Purewal et al.
patent: 6177121 (2001-01-01), Elkin et al.
patent: 6369103 (2002-04-01), Behounek et al.
patent: 6414011 (2002-07-01), Hogenkamp et al.
patent: 6506779 (2003-01-01), Cheng et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 2001/0034364 (2001-10-01), Gasper et al.
patent: 2002/0048746 (2002-04-01), Lynch et al.
patent: 2002/0147197 (2002-10-01), Newman et al.
patent: 2002/0156122 (2002-10-01), Mach
patent: 2003/0064967 (2003-04-01), Luchoomun et al.
patent: 2003/0087430 (2003-05-01), Catron et al.
patent: 2003/0114495 (2003-06-01), Finke et al.
patent: 2004/0122077 (2004-06-01), Walsh
patent: 2004/0127692 (2004-07-01), David et al.
patent: 2004/0192667 (2004-09-01), Makriyannis et al.
patent: 2005/0043364 (2005-02-01), Kennedy et al.
patent: 2005/0129729 (2005-06-01), Schreiner
patent: 2005/0261354 (2005-11-01), Griffin et al.
patent: 2005/0272770 (2005-12-01), Griffin et al.
patent: 2005/0282883 (2005-12-01), Griffin et al.
patent: 2005/0288306 (2005-12-01), Griffin et al.
patent: 2006/0084695 (2006-04-01), Griffin et al.
patent: 0436851 (1991-07-01), None
patent: 07267931 (1995-10-01), None
patent: 08217754 (1996-08-01), None
patent: 10162430 (1998-06-01), None
patent: 2002122952 (2002-04-01), None
patent: WO 93/09100 (1993-05-01), None
patent: WO 95/06032 (1995-03-01), None
patent: WO 98/06702 (1998-02-01), None
patent: WO 01/37876 (2001-05-01), None
patent: WO 01/93806 (2001-12-01), None
patent: WO 03/068738 (2003-08-01), None
patent: WO 03/086379 (2003-10-01), None
patent: WO 03/086418 (2003-10-01), None
patent: WO 04/069824 (2004-08-01), None
patent: WO 04/105752 (2004-12-01), None
Chan et al. Inhibitors of Cholesterol Biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a Novel Series of HMG-CoA Reductase Inhibitors. J. Med. Chem. 1993, 36, 3646-3657.
Awasthi, et al. CD40 Signaling Is Impaired In L. Major-Infected Macrophages And Is Rescued By A P38MAPK Activator Establishing A Host-Protective Memory T Cell Response.J. Exp. Med., 2003; 197(8): 1037-1043.
Bangham, et al. Diffusion Of Univalent Ions Across The Lamellae Of Swollen Phospholipids.J. Mol. Biol., 1965; 13:238-252.
Barros, et al. Evidence Of Two Mechanisms For The Activation Of The Glucose Transporter GLUTI by Anisomycin: p38 (MAP Kinase) Activation And Protein Synthesis Inhibition In Mammalian Cells.J. Physiol.1997; 504: 517-525.
Barry, Brian W. Dermatological Formulations: Percutaneous absorption.Marcel Dekker Inc.New York, NY; 1983.
Blumberg, et al. Animal Models Of Mucosal Inflammation And Their Relation To Human Inflammatory Bowel Disease.Current Opinion in Immunology.1999; 11: 648-656.
Bocan, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation.Athersclerosis.1994; 111:127-142.
Bocan, et al. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.Biochimica et Biophysica Acta.1992; 1123(2):133-144.
Boisemenu, et al. Insights From Mouse Models Of Colitis.Journal of Leukocyte Biology.2000; 67(3): 267-278.
Cantatore, et al. Evaluation of Bone Turnover and Osteoclastic Cytokines in Early Rheumatoid Arthritis Treated with Alendronate.J. Rheumatolgy.1996; 26(11):2318-2323.
Chakravarty, et al. Chapter 18: Inhibitors of p38α MAP Kinase.Annual Reports in Medicinal Chemistry.2002; 37:177-186.
Chan, et al. Inhibitors of cholesterol biosynthesis, 1. 3,5-dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors.J. Med. Chem.1993; 36(23): 3646-3657.
Clerk, et al. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs).FEBS Letters1998; 426: 93-96.
Curtin, et al. Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis.Br. J. Cancer.2002; 87(10): 1188-1194.
Dhawan, et al. Critical role of p42/44MAPK activation in anisomycin and hepatocyte growth factor-induced LDL receptor expression: activation of Raf-1/MEK-1/p42/44MAPK cascade alone is sufficient to induce LDL receptor expression.J. Lipid Res.1999; 40: 1911-1919.
Evans, et al. Nitric Oxide And Bone.J Bone Miner Res.1996; 11(3): 300-305.
Forrester, et al. Increasing High-Density Lipoprotein Cholesterol in Dyslipidemia by Cholesteryl Ester Transfer Protein Inhibition—An Update for Clinicians.Circulation.2005; 111(14): 1847-1854.
Gennaro, A.Remington: The Science and Practice of Pharmacy.20th edition; Lippincott Williams & Wilkins; 2000.
Golenbock, et al. Lipid A-Like Molecules That Antagonize The Effects Of Endotoxins On Human Monocytes.Journal of Biological Chemistry.1991; 266(29):19490-19489.
Graul, et al. ZD-4522: Hypolipidemic HMG-CoA reductase inhibitor.Drugs of the Future, 1999; 24(5): 511-513.
Joyce, et al. Pravastatin, A 3-hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Renal Injury in an Experimental Model of Ischemia-Reperfusion.J. of Surgical Research.2001; 101(1): 79-84.
Karanewsky, et al. Phosphorus-containing inhibitors of HMG-CoA reductase 1. 4-[(2-Arylethyl) hydroxyphosphinyl]-3-hydroxy-butanoic Acids: a new class of cell-selective inhibitors of cholesterol biosynthesis.Journal of Medicinal Chemistry.1990; 33(11): 2952-2956.
Katznelson, et al. Dual Roles Of HMG-Coa Reductase Inhibitors In Solid Organ Transplantation: Lipid Lowering And Immunosuppression., Kidney Int. Suppl., 1995; 48(52): S112-115.
Katznelson, et al. Effect Of HMG-Coa Reductase Inhibitors On Chronic Allograft Rejection.Kidney Int Suppl.1999; 56(71): S117-121.
Katznelson, et al. The Effect Of Pravastatin On Acute Rejection After Kidney Transplantation—A Pilot Study.Transplantation.1996; 61(10):1469-1474.
Kiener, et al. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors.Intl. Immunopharmacol.2001; 1: 105-118.
Krause, et al. Inhibition of cholesterol synthesis in target tissues and extrahepatic organs after administration of HMG-CoA reductase inhibitors in normolipidaemic rats: organ selectivity and time course of the inhibition.Journal of Drug Development.1990; 3(Supplement 1): 255-257.
Kureishi, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.Nature Medicine.2000; 6(8); 1004-1010.
Nagai, et al. Effect of overproduction of interleukin 5 on dinitrofluorobenzene-induced allergic cutaneous response in mice.The Journal of Pharmacology and Experimental Therapeutics.1999; 288(1): 43-50.
Namazi, M.R. Statins: Novel Additions To The Dermatologic Arsenal?Experimental Dermatology.2004; 13: 337-339.
Nofer, et al. Involvement of CDC42 signaling in ApoA-1-induced cholesterol efflux.J. Biol. Chem.2003; 278(52): 53055-53062.
Ono, et al. The P38 Signal Transduction Pathway Activation And Function.Cell. Signal.2000; 12(1): 1-13.
Palinski, et al. Immunomodulatory effects of
Griffin John
Lanza Guido
Yu Jessen
Graffeo Michel
Marschel Ardin H.
Pharmix Corporation
Wilson Sonsini Goodrich & Rosati
LandOfFree
Compositions and treatments for inhibiting kinase and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and treatments for inhibiting kinase and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and treatments for inhibiting kinase and/or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3752584